Search

Your search keyword '"Farotti, L."' showing total 73 results

Search Constraints

Start Over You searched for: Author "Farotti, L." Remove constraint Author: "Farotti, L."
73 results on '"Farotti, L."'

Search Results

1. Author Correction: Common variants in Alzheimer’s disease and risk stratification by polygenic risk scores (Nature Communications, (2021), 12, 1, (3417), 10.1038/s41467-021-22491-8)

2. New insights into the genetic etiology of Alzheimer's disease and related dementias

3. New insights into the genetic etiology of Alzheimer's disease and related dementias

4. New insights into the genetic etiology of Alzheimer's disease and related dementias

5. Clinical and biomarker profiling of prodromal Alzheimerʼs disease in workpackage 5 of the Innovative Medicines Initiative PharmaCog project: a ‘European ADNI study’

6. Cross-sectional clinical, neuropsychological, neuroimaging, and neurophysiological characterization of mild cognitive impairment patients in WP5 PharmaCog/E-ADNI study: EP1105

7. White Matter Hyperintensities Are No Major Confounder for Alzheimer's Disease Cerebrospinal Fluid Biomarkers

8. Common variants in Alzheimer’s disease and risk stratification by polygenic risk scores

9. Common variants in Alzheimer’s disease and risk stratification by polygenic risk scores

10. Common variants in Alzheimer's disease and risk stratification by polygenic risk scores

11. Age and the association between apolipoprotein E genotype and Alzheimer disease: A cerebrospinal fluid biomarker-based case-control study

12. LATE-ONSET EPILEPSY WITH UNKNOWN ETIOLOGY: A PILOT STUDY ON NEUROPSYCHOLOGICAL PROFILE, CEREBROSPINAL FLUID BIOMARKERS, AND QUANTITATIVE EEG CHARACTERISTICS

13. Reciprocal Incremental Value of 18F-FDG-PET and Cerebrospinal Fluid Biomarkers in Mild Cognitive Impairment Patients Suspected for Alzheimer's Disease and Inconclusive First Biomarker

14. Alzheimer's disease and late-onset epilepsy of unknown origin: two faces of beta amyloid pathology

15. Cognitive performances in patients affected by late-onset epilepsy with unknown etiology: A 12-month follow-up study

16. Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry

17. Improved Cerebrospinal Fluid-Based Discrimination between Alzheimer's Disease Patients and Controls after Correction for Ventricular Volumes

18. Improved Cerebrospinal Fluid-Based Discrimination between Alzheimer's Disease Patients and Controls after Correction for Ventricular Volumes

19. Performance evaluation of an automated ELISA system for Alzheimer's disease detection in clinical routine

20. Biological confounders for the values of cerebrospinal fluid proteins in Parkinson's disease and related disorders

21. Validation of microRNAs in Cerebrospinal Fluid as Biomarkers for Different Forms of Dementia in a Multicenter Study

22. Cross-sectional clinical, neuropsychological, neuroimaging, and neurophysiological characterization of mild cognitive impairment patients in WP5 PharmaCog/E-ADNI study

23. Cross-sectional clinical, neuropsychological, neuroimaging, and neurophysiological characterization of mild cognitive impairment patients in WP5 PharmaCog/E-ADNI study

24. LATE-ONSET EPILEPSY WITH UNKNOWN ETIOLOGY: A PILOT STUDY ON NEUROPSYCHOLOGICAL PROFILE, CEREBROSPINAL FLUID BIOMARKERS, AND QUANTITATIVE EEG CHARACTERISTICS

25. Incremental value of amyloid-PET versus CSF in the diagnosis of Alzheimer’s disease

26. Resting-State EEG Alpha Rhythms Are Related to CSF Tau Biomarkers in Prodromal Alzheimer's Disease.

27. Author Correction: Common variants in Alzheimer's disease and risk stratification by polygenic risk scores.

28. Common variants in Alzheimer's disease and risk stratification by polygenic risk scores.

29. White Matter Hyperintensities Are No Major Confounder for Alzheimer's Disease Cerebrospinal Fluid Biomarkers.

30. Abnormalities of resting-state EEG in patients with prodromal and overt dementia with Lewy bodies: Relation to clinical symptoms.

31. Unraveling Pathophysiological Mechanisms of Parkinson's Disease: Contribution of CSF Biomarkers.

32. Age and the association between apolipoprotein E genotype and Alzheimer disease: A cerebrospinal fluid biomarker-based case-control study.

33. Abnormal cortical neural synchronization mechanisms in quiet wakefulness are related to motor deficits, cognitive symptoms, and visual hallucinations in Parkinson's disease patients: an electroencephalographic study.

34. Late-Onset Epilepsy With Unknown Etiology: A Pilot Study on Neuropsychological Profile, Cerebrospinal Fluid Biomarkers, and Quantitative EEG Characteristics.

35. Incremental value of amyloid-PET versus CSF in the diagnosis of Alzheimer's disease.

36. Cognitive performances in patients affected by late-onset epilepsy with unknown etiology: A 12-month follow-up study.

37. Differential diagnosis between Alzheimer's disease and other dementias: Role of cerebrospinal fluid biomarkers.

38. Biomarker-Based Signature of Alzheimer's Disease in Pre-MCI Individuals.

39. Parkinson's and Lewy body dementia CSF biomarkers.

40. The added value of Aβ42/Aβ40 in the CSF signature for routine diagnostics of Alzheimer's disease.

41. Diagnostic performance of a fully automated chemiluminescent enzyme immunoassay for Alzheimer's disease diagnosis.

42. Longitudinal cerebrospinal fluid biomarker trajectories along the Alzheimer's disease continuum in the BIOMARKAPD study.

43. Abnormalities of functional cortical source connectivity of resting-state electroencephalographic alpha rhythms are similar in patients with mild cognitive impairment due to Alzheimer's and Lewy body diseases.

44. Alzheimer's disease and late-onset epilepsy of unknown origin: two faces of beta amyloid pathology.

45. Levodopa may affect cortical excitability in Parkinson's disease patients with cognitive deficits as revealed by reduced activity of cortical sources of resting state electroencephalographic rhythms.

46. Two-Year Longitudinal Monitoring of Amnestic Mild Cognitive Impairment Patients with Prodromal Alzheimer's Disease Using Topographical Biomarkers Derived from Functional Magnetic Resonance Imaging and Electroencephalographic Activity.

47. Reciprocal Incremental Value of 18F-FDG-PET and Cerebrospinal Fluid Biomarkers in Mild Cognitive Impairment Patients Suspected for Alzheimer's Disease and Inconclusive First Biomarker.

48. Discovery, validation and optimization of cerebrospinal fluid biomarkers for use in Parkinson's disease.

49. Association between CSF biomarkers, hippocampal volume and cognitive function in patients with amnestic mild cognitive impairment (MCI).

50. Improved Cerebrospinal Fluid-Based Discrimination between Alzheimer's Disease Patients and Controls after Correction for Ventricular Volumes.

Catalog

Books, media, physical & digital resources